Just four days after unveiling top-line data from a Phase IV study on the efficacy of thyroid eye disease (TED) drug Tepezza, Horizon Therapeutics plc got an updated indication from the US Food and Drug Administration for the biologic, which analysts said might encourage payers to cover the drug in patients with less-severe disease. Tepezza (teprotumumab) is a key driver of Amgen, Inc.’s $27.8bn buyout of Horizon, and analysts said broader use is necessary to assure the deal is viable financially.
Horizon's Revised TED Indication Should Help Tepezza
Good News For Amgen, But Viridian Looms As Competition
With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.